Acadia reported third-quarter 2026 GAAP total revenues of $342 million, up 23% from a year earlier, with DAYBUE net sales up 39% to $140 million. Net income fell to $54 million, or $0.31 per diluted share, from $72 million, or $0.42, a year earlier. The company raised its 2026 DAYBUE net sales guidance and narrowed its total revenue range, while lowering its R&D expense guidance.
Q3 2026 GAAP total revenues were $342 million, up from $279 million in Q3 2025; NUPLAZID net sales were $202 million and DAYBUE net sales were $140 million.
Q3 2026 net income was $54 million, or $0.31 per diluted share, versus $72 million, or $0.42 per diluted share, in Q3 2025.
2026 DAYBUE net sales guidance raised to $505 to $520 million from $480 to $510 million; total revenue guidance narrowed to $1.265 to $1.295 billion from $1.24 to $1.30 billion.
Cash, cash equivalents and investment securities were $976 million at September 30, 2026, up from $820 million at December 31, 2025.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
From Acadia Pharmaceuticals's 10-Q and 10-K filings (SEC XBRL). YoY compares each quarter with the same quarter a year earlier; it is blank when the year-ago figure is missing or negative.
Annual results
Fiscal year
Revenue
Growth
EPS (diluted)
Growth
Net margin
FY2025
$1.07B
+11.9%
$2.30
+69.1%
36.5%
FY2024
$957.80M
+31.8%
$1.36
—
23.6%
FY2023
$726.44M
+40.4%
$-0.37
—
-8.4%
FY2022
$517.24M
+6.8%
$-1.34
—
-41.8%
FY2021
$484.14M
+9.6%
$-1.05
—
-34.7%
Frequently asked questions
When is Acadia Pharmaceuticals's next earnings date?
Acadia Pharmaceuticals has not announced a report date within the next three weeks. US companies usually report three to six weeks after each quarter ends; this page updates as soon as the date is on the calendar.
What did Acadia Pharmaceuticals earn last quarter?
For the quarter ended Sep 2026, Acadia Pharmaceuticals reported diluted EPS of $0.31 (-26.2% year over year) on revenue of $342.29M (+22.8%).
Where do these numbers come from?
Reported revenue, net income and EPS come from the company's own 10-Q and 10-K filings with the SEC (XBRL data). The report date and consensus estimate come from the Nasdaq earnings calendar.
Not investment advice. Figures can be restated by the company in later filings.